Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Financing Activities (2018 - 2025)

Arcturus Therapeutics Holdings' Cash from Financing Activities history spans 8 years, with the latest figure at $11.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 8622.39% year-over-year to $11.7 million; the TTM value through Dec 2025 reached $13.4 million, up 146.99%, while the annual FY2025 figure was $13.4 million, 146.99% up from the prior year.
  • Cash from Financing Activities reached $11.7 million in Q4 2025 per ARCT's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $47.0 million in Q1 2021 to a low of -$27.4 million in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $2.0 million, with a median of $296500.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 39740.68% in 2021, then crashed 8244.05% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $230000.0 in 2021, then plummeted by 1070.43% to -$2.2 million in 2022, then crashed by 735.89% to -$18.7 million in 2023, then surged by 100.72% to $134000.0 in 2024, then surged by 8622.39% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Cash from Financing Activities are $11.7 million (Q4 2025), $1.2 million (Q3 2025), and -$14.7 million (Q2 2025).